News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Stephen Liu, MD, Georgetown University School of Medicine

Articles by Stephen Liu, MD, Georgetown University School of Medicine

The Future of Lung Cancer Treatment

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Fundamentals of Mesothelioma

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Latest Updated Articles

Trials in Limited-Stage Small-Cell Lung Cancer
Published: October 26th 2020 | Updated:
Fundamentals of Mesothelioma
Published: October 26th 2020 | Updated:
Recent Advances in Small-Cell Lung Cancer
Published: October 26th 2020 | Updated:
Understanding Immune Response in Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:
Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:
Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer
Published: October 26th 2020 | Updated:

Trending on OncLive

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies